Back to EveryPatent.com
United States Patent | 6,166,047 |
Dull ,   et al. | December 26, 2000 |
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines, such as (3-(3-pyridyloxy)propyl)methylamine and (3-(5-bromo(3-pyridyloxy))propyl)methylamine.
Inventors: | Dull; Gary Maurice (6025 Shalloford Rd., Lewisville, NC 27023); Dobson; Grayland Page (4524 Princess Dr., Winston-Salem, NC 27127); Wagner; Jared Miller (5100 Ambercrest Dr., Apt. B2, Winston-Salem, NC 27106) |
Appl. No.: | 054130 |
Filed: | April 2, 1998 |
Intern'l Class: | C07D 213/63; C07D 213/65; A61K 031/44 |
Field of Search: | 546/303,300 514/351 |
4599336 | Jul., 1986 | Carson et al. | 514/259. |
4927838 | May., 1990 | Guthrie et al. | 514/337. |
5212188 | May., 1993 | Caldwell et al. | 514/357. |
5585388 | Dec., 1996 | Cosford et al. | 514/343. |
5597919 | Jan., 1997 | Dull et al. | 544/242. |
5604231 | Feb., 1997 | Smith et al. | 514/256. |
5616707 | Apr., 1997 | Crooks et al. | 544/242. |
5616716 | Apr., 1997 | Dull et al. | 546/300. |
5629325 | May., 1997 | Lin et al. | 117/18. |
5663194 | Sep., 1997 | Mewshaw | 514/456. |
5663356 | Sep., 1997 | Ruecroft et al. | 546/300. |
5726316 | Mar., 1998 | Crooks et al. | 546/311. |
5731314 | Mar., 1998 | Bencherif et al. | 514/256. |
5811442 | Sep., 1998 | Bencherif et al. | 514/384. |
5824692 | Oct., 1998 | Lippiello et al. | 514/343. |
5861423 | Jan., 1999 | Caldwell et al. | 514/351. |
Foreign Patent Documents | |||
0 142 057 | Oct., 1984 | EP. | |
0 559 413 | Sep., 1993 | EP. | |
0 571 139 | Nov., 1993 | EP. | |
0 230 035 | Oct., 1994 | EP. | |
WO 94/08992 | Apr., 1994 | WO. | |
95/12612 | May., 1995 | WO. | |
WO 96/40682 | Dec., 1996 | WO. | |
WO 97/19059 | May., 1997 | WO. | |
WO 97 40011 | Oct., 1997 | WO. | |
97/42205 | Nov., 1997 | WO. | |
98/25920 | Jun., 1998 | WO. |
Abreo, Melwyn A. et al., Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors, J. Med. Chem., 39, 817-825 (1996). Bannon, A. W. et al., Broad-Sprectrum, Non-Opiod Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors, Science, vol. 29, 77-81, 1998. Elliott, Richard L. et al., 2-(Aryloxymethyl) Azacyclic Analogues as Novel Nicotinic Acetylcholine Receptor (nAChR) Ligands, Bioorganic & Medicinal Chemistry Letters, vol. 6, 19, 2283-2288, (1996). Elliott Richard L. et al., Novel 2-(2'-Furo (3,2-b) Pyridinyl) Pyrrolidines: Potent Neuronal Nicotinic Acetylcholine Receptor Ligands, Bioorganic & Medicinal Chemistry Letters, vol. 7, 21, pp. 2703-2708, 1997. Holladay, Mark W. et al., Identification and Initial Structure-Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropy ridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine Receptors, J. Med. Chem., vol. 41, No. 4, pp. 407-412, 1998. Holladay, Mark W. et al., Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery, J. Med. Chem., vol. 40, No. 26, pp. 4169-4194, 1997. Lin, Nan-Horng et al., Synthesis and Structure-Activity Relationships of Pyridine-Modified Analogs of 3-(2-((S)-Pyrrolidinyl Methoxy) Pyridine, A084543, A Potent Nicotinic Acetylcholine Receptor Agonist, Bioorganic & Medicinal Chemistry Letters, 8, pp. 249-254, 1998. Lin, Nan-Horng et al., Structure-Activity Studies on 2-Methyl-3-(2(S)-pyrrolidinylmethoxy) pyrodine (ABT-089) : An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-Enchancing Properties, J. Med. Chem., vol. 40, pp. 385-390, 1997. Bleicher, Leo et al., Synlett, pp. 1115-1116 (1995). Lippiello, P. et al., JPET, vol. 279, No. 3, pp. 1422-1429 (1996). Bencherif, M. et al., JPET, vol. 279, No. 3, pp. 1413-1421 (1996). Tilley, J.W. et al., J. Med. Chem., vol. 30, pp. 185-193 (1987). Guthrie, R. W. et al., J. Med. Chem., vol. 32, pp. 1820-1835 (1989). Unangst, P.C. et al., J. Med. Chem., vol. 40, pp. 4026-4029 (1997). Iwakura, Y. et al., Bulletin of the Chemical Society of Japan, vol 43, pp. 2531-2535 (1970). Schaeffer, J. C. et al., J. of Pharm. Sciences, vol. 65(1), pp. 122-126 (1976). Arora S. K. et al., J. Med. Chem., vol. 30, pp. 918-924 (1987). Buschauer, A., Eur. J. Med. Chem., vol. 23, pp. 1-6 (1988). Kawase, M. et al., Biochemical Pharmacology, vol. 31, No. 18, pp. 2983-2988 (1982). Lever, Jr., O.W. et al., J. Med. Chem., vol. 28, pp. 1870-1874 (1985). Pierson, M. E. et al., J. Med. Chem., vol. 32, pp. 859-863 (1989). Ismaiel, A. M. et al., J. Med. Chem., vol. 40 (26), pp. 4415-4419 (1997). Brenner J. B. et al., Aust. J. Chem., vol. 37, pp. 129-141 (1984). Mitanl, K. et al., Chem. Pharm. Bull., vol. 36(10), pp. 4103-4120 (1988). Mitanl, K. et al., Chem. Pharm. Bull., vol. 36(1), pp. 373-385 (1988). Brenner, J. B. et al., Aust. J. Chem., vol. 37, pp. 129-141 (1984). Wubbels, G. G. et al., J. Org. Chem., vol. 50, pp. 4499-4504 (1985). Wubbels, G. G. et al., Tetrahedron Letters, vol. 30, No. 47, pp. 6477-6480 (1989). Wubbels, G. G. et al., J. Org. Chem., vol. 60, pp. 2960-2961 (1995). Mewshaw, R. E. et al., J. Medicinal Chem., vol. 40, No. 26, pp. 4235-4256 (1997). Mutai, K. et al., Chemistry Letters, pp. 931-932 (1978). |